Biotech Macrogenics News Portfolio

Macrogenics Submits Biologics License Application for Margetuximab to FDA

Biotech News | 19.12.2019

Macrogenics, the US oncology company and member of our Biotech Investments Model Portfolio, today...

Biotech Macrogenics News Portfolio

Pfizer Stops Collaboration with Macrogenics on a Bispecific Antibody for Solid Tumors

Biotech News | 29.10.2019

Macrogenics has to digest a severe setback as Pfizer plans to stop a collaboration on a bispecific...

Biotech Macrogenics News Portfolio

Macrogenics Stocks Down 15% after Presentation of Updated Survival Data for Margetuximab

Biotech News | 23.10.2019

Shares of the Biotech Investments Model Portfolio member Macrogenics are down 15% to $9.38 today...

Biotech Macrogenics News Portfolio

Macrogenics Presents Updated Analysis of its Phase 2 Trial with Margetuximab in Metastatic Gastroesophageal Cancer: Share Gains more than 4%

Biotech News | 30.09.2019

Macrogenics, a US biotechnology company focusing on the development of novel antibody therapies for...

Biotech Macrogenics News Portfolio

Macrogenics Publishes Business and Pipeline Update for the Second Quarter of 2019, Share Price Falls Slightly

Biotech News | 31.07.2019

Our Model Portfolio member Macrogenics, which specializes in the development of innovative antibody...

Macrogenics Portfolio Stock Recommendations

Macrogenics: Buy!

Biotech News | 26.07.2019

Macrogenics is an American biotech company focused on the development of innovative antibody...